HC Wainwright Has Positive Forecast for OLMA Q3 Earnings

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Equities researchers at HC Wainwright lifted their Q3 2025 EPS estimates for Olema Pharmaceuticals in a research report issued on Tuesday, September 2nd. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.43) per share for the quarter, up from their prior forecast of ($0.82). The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q4 2025 earnings at ($0.51) EPS and FY2026 earnings at ($2.30) EPS.

A number of other equities research analysts also recently weighed in on OLMA. Citigroup boosted their price target on shares of Olema Pharmaceuticals from $20.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, August 12th. The Goldman Sachs Group dropped their price target on shares of Olema Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, May 14th. Zacks Research upgraded shares of Olema Pharmaceuticals to a “strong sell” rating in a report on Monday, August 11th. JPMorgan Chase & Co. boosted their price objective on shares of Olema Pharmaceuticals from $28.00 to $29.00 and gave the company an “overweight” rating in a report on Thursday, August 14th. Finally, Oppenheimer restated an “outperform” rating and set a $22.00 price objective on shares of Olema Pharmaceuticals in a report on Wednesday. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $24.00.

Olema Pharmaceuticals Trading Up 30.9%

OLMA opened at $8.31 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.09 and a quick ratio of 11.09. The company has a market cap of $570.32 million, a price-to-earnings ratio of -4.20 and a beta of 1.92. The firm has a 50 day simple moving average of $5.14 and a 200 day simple moving average of $4.67. Olema Pharmaceuticals has a fifty-two week low of $2.86 and a fifty-two week high of $13.93.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08).

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Thrivent Financial for Lutherans bought a new position in Olema Pharmaceuticals in the second quarter valued at approximately $308,000. Bridgeway Capital Management LLC bought a new position in Olema Pharmaceuticals in the second quarter valued at approximately $213,000. Birchview Capital LP bought a new position in Olema Pharmaceuticals in the second quarter valued at approximately $571,000. Ameriprise Financial Inc. lifted its stake in Olema Pharmaceuticals by 193.4% in the second quarter. Ameriprise Financial Inc. now owns 1,172,863 shares of the company’s stock valued at $4,996,000 after buying an additional 773,064 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in Olema Pharmaceuticals by 46.7% in the second quarter. The Manufacturers Life Insurance Company now owns 22,442 shares of the company’s stock valued at $96,000 after buying an additional 7,146 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.